Quarterly report · Q2
8095.TEDINET S100U1J4
Period2023-12-01 → 2024-05-31
Filed2024-07-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥28.1bn | 2023-12-01 → 2024-05-31 | Cons. | Net sales |
| Revenue | ¥52.0bn | 2022-12-01 → 2023-11-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥26.9bn | 2022-12-01 → 2023-05-31 | Cons. | Net sales |
| Operating income | ¥1.3bn | 2023-12-01 → 2024-05-31 | Cons. | Operating income |
| Operating income | ¥206m | 2022-12-01 → 2023-05-31 | Cons. | Operating income |
| Ordinary income | ¥1.4bn | 2023-12-01 → 2024-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.4bn | 2022-12-01 → 2023-11-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥282m | 2022-12-01 → 2023-05-31 | Cons. | Ordinary income |
| Profit before tax | ¥1.1bn | 2023-12-01 → 2024-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥66m | 2022-12-01 → 2023-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥705m | 2023-12-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.2bn | 2022-12-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥229m | 2022-12-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥701m | 2023-12-01 → 2024-05-31 | Cons. | Profit loss |
| Net income | −¥237m | 2022-12-01 → 2023-05-31 | Cons. | Profit loss |
| Total assets | ¥66.5bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥67.3bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥64.8bn | at 2023-05-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥37.4bn | at 2024-05-31 | Cons. | Liabilities |
| Total liabilities | ¥38.7bn | at 2023-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥29.1bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥28.6bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥26.6bn | at 2023-05-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.7bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.9bn | at 2023-11-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.6bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.8bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.3bn | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.8bn | at 2022-11-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.3bn | 2023-12-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.6bn | 2022-12-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥804m | 2022-12-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.5bn | 2023-12-01 → 2024-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.8bn | 2022-12-01 → 2023-11-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.0bn | 2022-12-01 → 2023-05-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.9bn | 2023-12-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2022-12-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥639m | 2022-12-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥17.75 | 2023-12-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥11.42 | 2024-03-01 → 2024-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.47 | 2022-12-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.81 | 2022-12-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-0.56 | 2023-03-01 → 2023-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 43.5% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.3% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-12-01 → 2024-05-31 | ¥26m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-12-01 → 2024-05-31 | ¥18m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-12-01 → 2024-05-31 | ¥8m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-12-01 → 2024-05-31 | −¥55m |
| Reconciling Itemsreconciling | revenue | 2023-12-01 → 2024-05-31 | −¥739m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-12-01 → 2024-05-31 | −¥739m |
| Reconciling Itemsreconciling | segment profit | 2023-12-01 → 2024-05-31 | ¥4m |
| jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segment | revenue | 2023-12-01 → 2024-05-31 | ¥10.9bn |
| jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segment | revenue external | 2023-12-01 → 2024-05-31 | ¥10.4bn |
| jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segment | revenue intersegment | 2023-12-01 → 2024-05-31 | ¥495m |
| jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segment | segment profit | 2023-12-01 → 2024-05-31 | ¥11m |
| jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segment | revenue | 2023-12-01 → 2024-05-31 | ¥6.8bn |
| jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segment | revenue external | 2023-12-01 → 2024-05-31 | ¥6.7bn |
| jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segment | revenue intersegment | 2023-12-01 → 2024-05-31 | ¥60m |
| jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segment | segment profit | 2023-12-01 → 2024-05-31 | ¥258m |
| jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segment | revenue | 2023-12-01 → 2024-05-31 | ¥5.6bn |
| jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segment | revenue external | 2023-12-01 → 2024-05-31 | ¥5.6bn |
| jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segment | revenue intersegment | 2023-12-01 → 2024-05-31 | ¥35m |
| jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segment | segment profit | 2023-12-01 → 2024-05-31 | ¥504m |
| jpcrp040300-q2r_E02585-000Medicalreportable segment | revenue | 2023-12-01 → 2024-05-31 | ¥5.6bn |
| jpcrp040300-q2r_E02585-000Medicalreportable segment | revenue external | 2023-12-01 → 2024-05-31 | ¥5.4bn |
| jpcrp040300-q2r_E02585-000Medicalreportable segment | revenue intersegment | 2023-12-01 → 2024-05-31 | ¥140m |
| jpcrp040300-q2r_E02585-000Medicalreportable segment | segment profit | 2023-12-01 → 2024-05-31 | ¥623m |
| —segment total | revenue | 2023-12-01 → 2024-05-31 | ¥28.8bn |
| —segment total | revenue external | 2023-12-01 → 2024-05-31 | ¥28.1bn |
| —segment total | revenue intersegment | 2023-12-01 → 2024-05-31 | ¥732m |
| —segment total | segment profit | 2023-12-01 → 2024-05-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-12-01 → 2024-05-31 | ¥28.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-12-01 → 2024-05-31 | ¥28.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-12-01 → 2024-05-31 | ¥739m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-12-01 → 2024-05-31 | ¥1.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-12-01 → 2023-05-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-12-01 → 2023-05-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-12-01 → 2023-05-31 | ¥669,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-12-01 → 2023-05-31 | −¥49m |
| Reconciling Itemsreconciling | revenue | 2022-12-01 → 2023-05-31 | −¥842m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-12-01 → 2023-05-31 | −¥842m |
| Reconciling Itemsreconciling | segment profit | 2022-12-01 → 2023-05-31 | ¥18m |
| jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segment | revenue | 2022-12-01 → 2023-05-31 | ¥9.7bn |
| jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segment | revenue external | 2022-12-01 → 2023-05-31 | ¥9.1bn |
| jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segment | revenue intersegment | 2022-12-01 → 2023-05-31 | ¥560m |
| jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segment | segment profit | 2022-12-01 → 2023-05-31 | −¥13m |
| jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segment | revenue | 2022-12-01 → 2023-05-31 | ¥8.9bn |
| jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segment | revenue external | 2022-12-01 → 2023-05-31 | ¥8.8bn |
| jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segment | revenue intersegment | 2022-12-01 → 2023-05-31 | ¥56m |
| jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segment | segment profit | 2022-12-01 → 2023-05-31 | ¥77m |
| jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segment | revenue | 2022-12-01 → 2023-05-31 | ¥4.4bn |
| jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segment | revenue external | 2022-12-01 → 2023-05-31 | ¥4.4bn |
| jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segment | revenue intersegment | 2022-12-01 → 2023-05-31 | ¥35m |
| jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segment | segment profit | 2022-12-01 → 2023-05-31 | −¥81m |
| jpcrp040300-q2r_E02585-000Medicalreportable segment | revenue | 2022-12-01 → 2023-05-31 | ¥4.7bn |
| jpcrp040300-q2r_E02585-000Medicalreportable segment | revenue external | 2022-12-01 → 2023-05-31 | ¥4.5bn |
| jpcrp040300-q2r_E02585-000Medicalreportable segment | revenue intersegment | 2022-12-01 → 2023-05-31 | ¥191m |
| jpcrp040300-q2r_E02585-000Medicalreportable segment | segment profit | 2022-12-01 → 2023-05-31 | ¥255m |
| —segment total | revenue | 2022-12-01 → 2023-05-31 | ¥27.7bn |
| —segment total | revenue external | 2022-12-01 → 2023-05-31 | ¥26.9bn |
| —segment total | revenue intersegment | 2022-12-01 → 2023-05-31 | ¥841m |
| —segment total | segment profit | 2022-12-01 → 2023-05-31 | ¥237m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-12-01 → 2023-05-31 | ¥27.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-12-01 → 2023-05-31 | ¥26.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-12-01 → 2023-05-31 | ¥842m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-12-01 → 2023-05-31 | ¥188m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 626
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02585-000FineChemicalsReportableSegmentsMember | 9680109000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02585-000HealthAndBeautyCareFoodReportableSegmentsMember | 8867981000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02585-000MedicalReportableSegmentsMember | 4709096000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02585-000IndustrialChemicalsReportableSegmentsMember | 4438053000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 27695241000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4343000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 27699584000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -842073000 | JPY |
| Net sales | Prior1YTDDuration | 26857511000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02585-000FineChemicalsReportableSegmentsMember | -12944000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02585-000HealthAndBeautyCareFoodReportableSegmentsMember | 76717000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02585-000MedicalReportableSegmentsMember | 254657000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02585-000IndustrialChemicalsReportableSegmentsMember | -81453000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 236977000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -48587000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 188390000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | 18094000 | JPY |
| Operating income | Prior1YTDDuration | 206484000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02585-000FineChemicalsReportableSegmentsMember | 10356595000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02585-000HealthAndBeautyCareFoodReportableSegmentsMember | 6702295000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02585-000MedicalReportableSegmentsMember | 5414972000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02585-000IndustrialChemicalsReportableSegmentsMember | 5599734000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 28073598000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 18078000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 28091676000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 28091676000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02585-000FineChemicalsReportableSegmentsMember | 495318000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02585-000HealthAndBeautyCareFoodReportableSegmentsMember | 60408000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02585-000MedicalReportableSegmentsMember | 140313000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02585-000IndustrialChemicalsReportableSegmentsMember | 35480000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 731520000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 7937000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 739458000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -739458000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02585-000FineChemicalsReportableSegmentsMember | 10851913000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02585-000HealthAndBeautyCareFoodReportableSegmentsMember | 6762704000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02585-000MedicalReportableSegmentsMember | 5555286000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02585-000IndustrialChemicalsReportableSegmentsMember | 5635214000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 28805119000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 26015000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 28831134000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -739458000 | JPY |
| Net sales | CurrentYTDDuration | 28091676000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02585-000FineChemicalsReportableSegmentsMember | 11105000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02585-000HealthAndBeautyCareFoodReportableSegmentsMember | 258082000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02585-000MedicalReportableSegmentsMember | 623289000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02585-000IndustrialChemicalsReportableSegmentsMember | 503898000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |